-+ 0.00%
-+ 0.00%
-+ 0.00%

On December 25, the official website of the State Drug Administration revealed that Cinda Biotech's ipimumab N01 injection was approved for marketing. Together with cindilizumab, it is used as a new adjuvant treatment for patients with highly unstable or mismatched colon cancer with operatively resectable IIB-III microsatellites. According to reports, this drug is the first domestically produced anti-CTLA-4 monoclonal antibody approved in China, and the first anti-CTLA-4 monoclonal antibody approved in the world for new adjuvant treatment of colon cancer.

Zhitongcaijing·12/25/2025 10:17:05
Listen to the news
On December 25, the official website of the State Drug Administration revealed that Cinda Biotech's ipimumab N01 injection was approved for marketing. Together with cindilizumab, it is used as a new adjuvant treatment for patients with highly unstable or mismatched colon cancer with operatively resectable IIB-III microsatellites. According to reports, this drug is the first domestically produced anti-CTLA-4 monoclonal antibody approved in China, and the first anti-CTLA-4 monoclonal antibody approved in the world for new adjuvant treatment of colon cancer.